Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure

Journal of Nephrology

Volumn 19, Issue 5, 2006, Pages 566-577

  Cozzolino, Mario ^a   Gallieni, Maurizio ^a   Brancaccio, Diego ^a   Arcidiacono, Teresa ^b   Bianchi, Giuseppe ^b   Vezzoli, Giuseppe ^b  

^a SAN PAOLO HOSPITAL   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Calcium; Chronic renal failure; Parathyroid hormone; Phosphate; Vitamin D

Indexed keywords

22 OXACALCITRIOL; CALCIFEDIOL; CALCITRIOL; CINACALCET; COLECALCIFEROL; CREATININE; DNA; DOXERCALCIFEROL; ERGOCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; VITAMIN D; VITAMIN D RECEPTOR;

BLOOD VESSEL CALCIFICATION; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; GENE REPRESSION; GENETIC TRANSCRIPTION; HEMODIALYSIS; HORMONE SYNTHESIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MINERAL METABOLISM; MORBIDITY; MORTALITY; NONHUMAN; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

CALCINOSIS; CALCIUM; CARDIOVASCULAR DISEASES; CREATININE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; RENAL OSTEODYSTROPHY; UP-REGULATION; VITAMIN D;

EID: 33947254019     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Reinhart TA, Ramberg CF, Horst RL. Comparison of receptor binding, biological activity, and in vivo tracer kinetics for 1,25-dihydroxyvitamin D3 and 1,25-dihydroxyvitamin D2 and its 24 epimer. Arch Biochem Biophys 1989; 273: 64-71.
2. Cunningham J, Makin H. How important is vitamin deficiency in uremia? Nephrol Dial Transplant 1997; 12: 16-8.
3. Khaw KT, Sneyed MJ, Compston J. Bone density, parathyroid hormone and 25-hydroxyvitamin D concentrations in middle aged women. BMJ 1992; 305: 373-6.
4. McKenna MJ, Freaney R. Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D. Osteoporos Int 1998; 8: S3-6.
5. Cannata JB, Alonso CG. Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. Nephrol Dial Transplant 2002; 17: 1875-8.
6. Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Moriniere P, Garabedian M, Eastwood J, Fournier A. Is low 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol. Kidney Int 1999; 55: 2169-77.
7. Wang M, Hercz Z, Sherrard DJ, Segre GV, Pei Y. Relationship between intact PTH 1-84 parathyroid hormone and bone histomorphometry parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995; 26: 836-44.
8. Le Boff MS, Kholmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999; 281: 1505-11.
9. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-Hydroxyvitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004; 116: 634-9.
10. Collins D, Jasani C, Fogelman I, Swaminathan R. Vitamin D and bone mineral density. Osteoporos Int 1998; 8: 110-4.
11. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM. Prince RI, Finkelstein JS. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338: 777-83.
12. Coen G, Mantella D, Manni M, Balducci A, Nofroni I, Sardella D, Ballanti P, Bonucci E. 25-Hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 2005; 68: 1840-5.
13. Lin R, White JH. The pleiotropic actions of vitamin D. Bioessays 2004; 26: 21-8.
14. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997; 96: 1755-60.
15. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52: 3-9.
16. Silver J, Bar Sela S, Naveh-Many T. Regulation of parathyroid cell proliferation. Curr Opin Nephrol Hypertens 1997; 6: 321-6.
17. Cozzolino M, Brancaccio D, Gallieni M, Galassi A, Slatopolsky E, Dusso A. Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol 2005; 18: 5-8.
18. Denda M, Finch J, Slatopolsky E. Phosphorus accelerated the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996; 28: 596-602.
19. Tominaga Y, Tsuzuki T, Uchida K, Haba T, Otsuka S, Ichimori T, Yamada K, Numano M, Tanaka Y, Takagi H. Expression of Pradl/cyclin D1, retinoblastoma gene product, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 1999, 55: 1375-83.
20. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19: 303-17.
21. Rodriguez M, Almaden Y, Hernandez A, Torres A. Effect of phosphate on the parathyroid gland: direct and indirect? Curr Opin Nephrol Hypertens 1996; 5: 321-8.
22. Portale AA, Halloran BP, Morris RC Jr. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989; 83: 1494-9.
23. Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 1998; 273: 5253-9.
24. Wang Q, Palnitkar S, Parfitt AM. Parathyroid cell proliferation in normal human parathyroid tissue: implications for the pathogenesis of hyperparathyroidism. Clin Endocrinol 1997; 46: 343-9.
25. Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso AS. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 2001; 60: 2109-17.
26. Brown EM. Calcium receptor and regulation of parathyroid hormone secretion. Rev Endocr Metab Disord 2000; 1: 307-15.
27. Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, Brown EM, Seidman JG, Seidman CE. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 1995; 11: 389-94.
28. Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, Delling G, Demay MB. Normalization of mineral on homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998; 139: 4391-6.
29. Kremer R, Bolivar I, Golztman D, Hendly GN. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 1989; 125: 935-41.
30. Szabo A, Merke J, Beier E, Mall G, Ritz E. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049-56.
31. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990; 86: 1313-9.
32. Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 2002; 62: 1196-207.
33. Dusso A, Cozzolino M, Lu Y, Sato T, Slatopolsky E. 1,25-Dihydroxyvitamin D downregulation of TGF/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure. J Steroid Biochem Mol Biol 2004; 89-90: 507-11.
34. Cordero JB, Cozzolino M, Lu Y, Vidal M, Slatopolsky E, Stahl PD, Barbieri MA, Dusso A. 1,25-Dihydroxyvitamin D downregulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem 2002; 277: 38965-71.
35. Martinez I, Saracho R, Montenegro J, Llach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11 (Suppl 3): 22-8.
36. Reichel H, Deibert B, Schmidt-Gayk H, Ritz E. Calcium metabolism in early chronic renal failure, implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991; 6: 162-9.
37. Eastwood JB, Harris E, Stamp TCB, De Wardener HE. Vitamin D deficiency in the osteomalacia of chronic renal failure. Lancet 1976; 2: 1209-21.
38. Van der Wielen RP, Lowik MR, Van den Berg H. deGroot L, Haller J, Mereiras W, Van Stavered WA. Serum vitamin D concentrations among elderly people in Europe. Lancet 1995; 346: 207-10.
39. Scharla SH. Prevalence of subclinical vitamin D deficiency in different European countries. Osteoporos Int 1998; 8: S7-12.
40. Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in non dialyzed patients with chronic renal failure. Kidney Int 1999; 55: 1019-27.
41. Messa P, Vallone C, Meoni G, Geatti O, Turrin D Passoni N, Cruciatti A. Direct in vivo assessment of parathyroid hormone calcium relationship curve in renal patients. Kidney Int 1994; 46: 1713-20.
42. Slovik DM, Adams JS, Neer RS. Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients. N Engl J Med 1981; 305: 3724.
43. Papapoulos SE, Clemens TL, Fraher LJ, Gleed J, O'Riordan JL. Metabolites of vitamin D in human vitamin D deficiency: effect of vitamin Dor 1,25-dihydroxycolecalciferol. Lancet 1980; 2: 612-5.
44. Battaille P, Achard JM, Fournier A, Boudailliez B, Westeel JD, El Espe N, Bergot C, Jans I, Lalau JD, Petit J, Henon G, Laval Jeantet MA, Bouillon R, Sebert JL. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991; 39: 1193-205.
45. Cogan MG, Covey CM, Arieff AI, Wisniewski A, Clark OH, Lazarowitz V, Leach W. Central nervous system manifestations of hyperparathyroidism. Am J Med 1978; 65: 963-70.
46. Mak RH, Bettinelli A, Turner C, Haycock GB, Chantler C. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab 1985; 60: 229-33.
47. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002; 17: 2094-105.
48. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephol 2001; 12: 2131-8.
49. Cozzolino M, Dusso A, Slatopolsky E. Role of calcium x phosphate product and bone associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001; 12: 2511-6.
50. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003; 14: S305-9.
51. Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003; 63: 1852-60.
52. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68: 429-36.
53. Jakoby MGt, Semenkovich CF. The role of osteoprogenitors in vascular calcification. Curr Opin Nephrol Hypertens 2000; 9: 11-5.
54. Brancaccio D, Cozzolino M. The mechanism of calcium deposition in soft tissues. Contrib Nephrol 2005; 149: 279-86.
55. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-37.
56. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-40.
57. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-83.
58. Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 2002; 13: 2299-308.
59. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003; 64: 1653-61.
60. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-52.
61. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (Suppl 3): 63-200.
62. Massry SG, Coburn JW, Lee DB, Jowsey J, Kleeman CR. Skeletal resistance to parathyroid hormone in renal failure: studies in 105 human subjects. Ann Intern Med 1973; 78: 357-64.
63. Disthabanchong S, Hassan H, McConkey CL, Martin KJ, Gonzalez EA. Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-101 osteoblast-like cells. Kidney Int 2004; 65: 897-903.
64. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, Segre GV, Fenton S, Sherrard DJ. Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int 1993; 44: 860-6.
65. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-21.
66. Cournot-Witmer G, Zingraff J, Plachot JJ, Escaig F, Lefevre R, Boumati P, Bourdeau A, Garabedian M, Galle P, Bourdon R, Drueke T, Balsan S. Aluminum localization in bone from hemodialyzed patients: relationship to matrix mineralization. Kidney Int 1981; 20: 375-8.
67. Birge SJ, Haddad JG. 25-Hydroxycholecalciferol stimulation of muscle metabolism. J Clin Invest 1975; 56: 1100-7.
68. Schomig M, Ritz E. Management of disturbed calcium metabolism in uremic patients: Part 1: use of vitamin D metabolites. Nephrol Dial Transplant 2000; 15 (Suppl 5): 18-24.
69. Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 1988; 67: 929-36.
70. Baker LR, Abrams L, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989; 35: 661-9.
71. Bianchi ML, Colantonio G, Campanini F, Rossi R, Valenti G, Ortolani S, Buccianti G. Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 1994; 9: 1595-9.
72. Christiansen C, Rodbro P, Christiansen MS, Hartnack B. Is 1,25-dihydroxycholecalciferol harmful to renal function in patients with chronic renal failure? Clin Endocrinol 1981; 15: 229-36.
73. Ritz E, Kuster S, Schmidt-Gayk H, Stein G, Scholz C, Kraatz G, Heidland A. Low dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure. Nephrol Dial Transplant 1995; 10: 2228-34.
74. Baker LR, Abram L, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989; 35: 661-9.
75. Herrmann P, Ritz E, Schmidt-Gayk H, Schafer I, Geyer J, Nonnast-Daniel B, Koch KM, Weber U, Horl W, Haas-Worle A. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron 1994; 67: 48-53.
76. Indridason OS, Quarles LD. Comparison of treaunent for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int 2000; 57: 282-92.
77. Levine BS, Song M. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996; 7: 488-96.
78. Goodman WG, Ranfirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160-6.
79. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, Segre GV, Fenton S, Sherrard DJ. Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int 1993; 44: 860-6.
80. Akizawa T, Kurokawa K. Long-term clinical effect of maxacalcitol on hemodialysis patients with secondary hyperparathyroidism. Clin Calcium 2002; 12: 781-8.
81. Akizawa T, Ohashi Y, Akiba T, Suzuki M, Nishizawa Y, Ogata E, Slatopolsky E, Kurokawa K. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism. Ther Apher Dial 2004; 8: 480-91.
82. Dusso AS, Negrea L, Finch J, Kamimura S, Lopez-Hilker S, Mori T, Nishii Y, Brown A, Slatopolsky E. The effect of 22-oxacalcitriol on serum calcitriol. Endocrinology 1992; 130: 3129-34.
83. Brown AJ, Finch JL, Lopez-Hilker S, Dusso A, Ritter C, Pernalete N, Slatopolsky E. New active analogues of vitamin D with low calcemic activity. Kidney Int 1990; 29 (Suppl 29): 22-7.
84. Lach F, Yudd M. Paricalcitol in dialysis patients with calcitriol resistant secondary hyperparathyroidism. Am J Kidney Dis 2001; 38 (Suppl 5): 45-50.
85. Martin KJ, Gonzales E, Lindberg J, Taccetta C, Amdahl M, Malhotra K, Llach F. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a vitamin D analogues for secondary hyperparathyroidism: a double-blind multicenter randomized trial. Am J Kidney Dis 2001; 38: s57-63.
86. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001; 38 (5 Suppl 5): S51-6.
87. Sprague SM, Llach F, Amdhal M, Taccetta C, Battle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-90.
88. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JN, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-56.
89. Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients. Nephrol Dial Transplant 2004; 19: 1174-81.
90. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport. J Lab Clin Med 2002; 139: 279-84.
91. Finch J, Brown AJ, Slatopolsky E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-l,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999; 10: 980-5.
92. Coburn JW, Maung HM, Elangovan L, Germain J, Lindberg JS, Sprague SM, Williams ME, Bishop CW. Doxercalciferol safely suppress PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004; 43: 877-90.
93. Tan AU Jr, Levine BS, Mazess RB, Kyllo DM, Bishop CW, Knutson JC, Kleinman KS, Coburn JW. Effective suppression of parathyroid hormone by 1-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51: 317-23.
94. Frazao JM, Chesney RW, Coburn JW. Intermittent oral 1 -hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in hemodialysis patients. Nephrol Dial Transplant 1998; 3: 68-72.
95. Rix M, Eskildsen O, Olgaard K. Effect of 18 months of treatment with alphacalcidiol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 2004; 19: 870-6.
96. Mawer EB, Jones G, Davies M, Still PE, Byford V, Schroeder NJ, Makin HL, Bishop CW, Knutson JC. Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum. J Clin Endocrinol Metab 1998; 83: 2156-66.